In SURPASS-2, which compared tirzepatide to semaglutide (a GLP-1 receptor agonist) in patients taking metformin, tirzepatide 5 mg, 10 mg, and 15 mg doses achieved mean HbA1c reductions of 2.01%, 2.24%, and 2.30% respectively from baseline, compared to 1.86% with semaglutide 1 mg
ELIXA is the first CV outcomes study for any drug in the GLP-1 agonist and found that Lyxumia had a neutral effect on heart failure and other cardiovascular problems, as well as a modest benefit for weight control and no increase of risk for hypoglycaemia or pancreatic injury
The compound has never received market authorization in Canada or anywhere else, and Metabolic Pharmaceuticals terminated clinical development in 2007 after the Phase IIb obesity trial failed
Hence, the aim of this review is to depict the current molecular and pharmacological knowledge on glutathione, focusing on the available studies related to its therapeutic activity in NAFLD
Key ingredients: alpha-lipoic acid, tranexamic acid, vitamin C, and B-complex vitamins
.png)
